Across TCGA pan-cancer cohorts, SULT2A1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SULT2A1 data layer compared with 20 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SULT2A1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SULT2A1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
PDAC are the cancer types where SULT2A1 mass-spec protein most reproducibly stratifies survival.